Nabriva Therapeutics plc

25-28 North Wall Quay,

IFSC, Dublin 1, Ireland

April 25, 2018

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C.  20549

Re:Nabriva Therapeutics plc

Registration Statement on Form S-3

File No. 333-223799

Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Nabriva Therapeutics plc (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-223799), as amended (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on April 27, 2018, or as soon thereafter as practicable.

Very truly yours,
NABRIVA THERAPEUTICS PLC
By:	/s/ Colin Broom
	Name: Colin Broom
	Title: Chief Executive Officer